



## Appointment of Joint Corporate Broker

February 3, 2021

Released : February 03, 2021 16:35

RNS Number : 9190N

MaxCyte, Inc.

03 February 2021

MaxCyte, Inc.

("MaxCyte" or the "Company")

### Appointment of Joint Corporate Broker

Gaithersburg, Maryland - 3 February 2021: MaxCyte (LSE: MXCT, MXCL), a global cell-engineering and life sciences company, announces the appointment of Stifel Nicolaus Europe Limited as the Company's Joint Corporate Broker with immediate effect alongside existing Joint Corporate Brokers Panmure Gordon and Numis.

MaxCyte

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Financial Officer

*Nominated Adviser and Joint Corporate Broker*

+44 (0) 20 7886 2892

Panmure Gordon (UK) Limited

Emma Earl / Freddy Crossley (Corporate Finance)

Rupert Dearden (Corporate Broking)

*Joint Corporate Broker*

+44 (0) 20 7260 1000

**Numis Securities Ltd.**

James Black / Duncan Monteith / Matthew O'Dowd

*Joint Corporate Broker*

**Stifel Nicolaus Europe Limited**

+44 (0) 20 7710 7600

Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking)

Nick Adams (Corporate Broking)

*Financial PR Adviser*

+44 (0)203 709 5700

Consilium Strategic Communications

maxcyte@consilium-comms.com

Mary-Jane Elliott / Chris Welsh

### **About MaxCyte**

MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Company's technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit [www.maxcyte.com](http://www.maxcyte.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPTJMFTMTBMBPB